Dear Friends,

 width=

As 2023 is wrapping up, we want to thank all of you who support the A-T Children’s Project and the impact you have in supporting our mission of finding life-improving therapies and a cure for A-T. As most of you know, A-T families and friends raise most of our funds through their grassroots efforts, and this year was no exception! Families and friends hosted new and returning golf tournaments, 5K runs, on-line campaigns, marathons, a family fun day, book sales, a horse show, dinners with auctions – and the list goes on!

As a small organization, we are “punching above our weight,” accelerating research not just by financially supporting laboratories but also through A-T families volunteering to participate in research studies. Our comprehensive, industry-grade approach to developing treatments – trying hard to anticipate the research tools, biospecimens and biomarkers that will be needed far in advance – is starting to gain traction in attracting not only academic researchers but also biotechnology and pharmaceutical companies. We wouldn’t be where we are now if it weren’t for the tireless efforts of our volunteers and supporters, coming together with a singular goal.

Thank you to our fundraisers and their donors who make it happen!

If you haven’t had a chance to make a year-end donation, please consider doing so here.

We are looking forward to A-T research advances in the coming year! Wishing you and yours a very Happy New Year.

All the best,

Jennifer Thornton, Executive Director

DONATE

For those of you who haven’t had a chance to read it yet, here is the research update that Brad Margus (Founder, Volunteer Board Chair and A-T Dad) sent out on Giving Tuesday a few weeks ago, when our community generously helped us hit our goal!

Related News

May 18 @ 1:38 am

Shining a Light on A-T at the IlluminATion Ball

The A-TCP is hosting IlluminATion: A BioPharma Leadership Ball on May 11 in Boston to shine a light

more
May 18 @ 1:38 am

NEAT Study – Phase 3 Clinical Trial of EryDex, a Low-Dose Steroid

Quince Therapeutics is advancing a phase 3 clinical trial to evaluate EryDex, a potential new treatment for ataxia-telangiectasia

more
May 18 @ 1:38 am

Measles Prevention in A-T: Recommendations from Dr. Lederman

Dr. Lederman of the A-T Clinical Center provides recommendations to keep people with A-T from catching measles.

more
May 18 @ 1:38 am

A-T Biomarker Development Initiative Now Recruiting

On December 18, the A-T Children’s Project sent out the below email to A-T parents in the United…

more